Saturday, 17 August 2013

Siemens introduces the future of molecular imaging

Main Category: Radiology / Nuclear Medicine
Also Included In: Medical Devices / Diagnostics
Article Date: 16 Aug 2013 - 2:00 PDT Current ratings for:
Siemens introduces the future of molecular imaging
not yet ratednot yet rated

Siemens Healthcare has launched a new platform with the potential to change how molecular imaging is performed. The Symbia Intevo™ is the world's first xSPECT system. It combines the high sensitivity of single-photon emission computed tomography (SPECT) with the high specificity of CT, completely integrating the data from the two modalities, to generate high resolution and, for the first time, quantitative images[1]. The system demonstrates Siemens' innovation and competitiveness, key components of the Healthcare Sector's Agenda 2013 two-year initiative.

The new Symbia Intevo xSPECT system reconstructs both the SPECT and CT portions of an image into a much higher frame of reference than other systems for precise, accurate alignment facilitating the extraction and deep integration of medically relevant information. This ability is the basis for differentiating between tissue boundaries in bone imaging. With xSPECT Bone clinicians can potentially provide additional support for detection and distinguishing between cancerous lesions and degenerative disorders. The Symbia Intevo's precise alignment of SPECT and CT provides clinicians with essential volumetric information from the CT scan, enabling accurate and consistent quantitative assessment meaning the clinician can apply quantitative information to assess whether a patient's condition has regressed, stabilised or progressed.

Full body Scan
SPECT and CT integrated.

The Symbia Intevo uses more CT data than ever before, but Siemens is still able to limit patient dose by offering Combined Applications to Reduce Exposure (CARE). The system uses AUTOFORM collimator, capturing up to 26 more counts, helping boost image acquisition time and patient throughput.

"Siemens Healthcare anticipates the new Symbia Intevo technology will improve the quality of care, while helping to reduce costs," states Lawrence Foulsham, Molecular Imaging Product Manager at Siemens Healthcare. "Siemens recognises that these two elements must go hand-in-hand, and with our new molecular imaging solutions, we can demonstrate our commitment to true innovation leadership by overcoming the limitations of conventional SPECT systems to help provide answers to the toughest clinical questions in the safest and most efficient way possible."

Article adapted by Medical News Today from original press release. Source:

1. Pending 510(k) clearance,

Siemens


Visit our radiology / nuclear medicine section for the latest news on this subject.

1. Pending 510(k) clearance,

Siemens

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Siemens. "Siemens introduces the future of molecular imaging." Medical News Today. MediLexicon, Intl., 16 Aug. 2013. Web.
16 Aug. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Siemens introduces the future of molecular imaging'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

No comments:

Post a Comment